StockMirror — Stock Screener

GRANULES Q4 FY26 Results & Earnings Analysis

Sentiment: Good (Confidence: high)

Earnings Summary

Granules India reported a strong finish to FY26 with record revenue, gross margin expansion, and a return to profitability for its peptide CDMO business. The company is successfully executing a strategic shift towards complex generics and CDMO services, evidenced by a 100 bps expansion in EBITDA margins. However, the near-term outlook is cautiously optimistic due to rising input costs from geopolitical tensions and the uncertainty over the timing of the U.S. FDA's re-inspection at its key Gagillapur plant. Management's focus remains on executing its strategy and navigating these external headwinds.

Management Tone

Revenue Growth Drivers

Growth vs Margin Focus

Management is pursuing a strategy of 'value-led growth'. They are investing in high-growth areas (peptides, complex generics) that inherently offer higher margins. The goal is to achieve sustainable and differentiated growth while maintaining strong margins.

About Granules India Limited

Granules India Limited (GRANULES) is listed on NSE. View the latest earnings analysis, AI-powered insights, and sentiment data on StockMirror.

Explore More